Short-, Intermediate-, Long-Acting Insulins

Slides:



Advertisements
Similar presentations
New Insulin Formulations Guillermo Umpierrez, MD, FACP, FACE Professor of Medicine Emory University School of Medicine Part 1.
Advertisements

Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.
What's New in Basal Insulin for Diabetes
R2. Sun Hee Park/Prof. Moon Chan Choi
Upfront Combination Therapy vs Step-Up Approach for PAH:
Recommendation In people with clinical cardiovascular disease in whom glycemic targets are not met, a SGLT2 inhibitor with demonstrated cardiovascular.
Type 1 Diabetes: Meters, Pumps, and Transitions to Adulthood
Diabetic Dyslipidemia in Practice
COPD by the Guidelines.
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Applying Data to Practice
Diabetes and Risk of CV Outcomes
Special Consideration in Insulin Therapy
Optimizing Outcomes in Short Bowel Syndrome With IF
Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.
Using the AGP to Standardize Glucose Reporting
New Patient-Friendly Options for Managing Insulin Dosing
The Next Generation of Basal Insulins
Understanding Biologics
Modern Strategies for Basal Insulin Use in T2D
Patient Case Discussions in T2D: What Intensification Plan Is Best?
Insulin Innovation.
Updates on Outcomes for Novel T2D Therapies
Insulin Intensification Strategies in Later-Stage Type 2 Diabetes Mellitus.
Agenda. Insulin Intensification Strategies: An Expert Perspective from Asia-Pacific.
How Early Should Basal Insulin Be Used in T2D Management?
SGLT2 Inhibitors in the Modern Era: Why and Where?
Examining CV Effects of Basal Insulin Therapy
What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?
Innovative Insulin Combinations: A New strategy for the Person With T2DM.
Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?
Emerging Basal Insulins for Diabetes
GLP-1 Receptor Agonists: How Early Is Appropriate?
Decision-making in the eRA of Treating to Target
Are We Closer to Personalized Medicine in MS?
Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
What Is the Role of Injectables in the Modern Era of MS Treatment?
Novel Basal Insulin Formulations in the Modern Era of T2D Management
Insulin Innovation.
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
Aspirin in Cardioprevention:
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Translating the Latest and Greatest Advances in PAH Into Clinical Practice.
Predictive Low Glucose Suspend (PLGS)
Novel Approaches to T1D Management
T2DM Management.
Better Diabetes Control With Novel Basal Insulins
Program Goals Overview Is NEDA a Reasonable Target?
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
Modern Advances in Glucose Monitoring
Program. Basal Insulin in the Modern Era The CDE's Role in Improving Utilization and Outcomes.
Advancements in Glucose Monitoring
Insulin Innovation.
Insulin in Diabetes Management: Effective Patient Selection Is Key
Statins, Obesity, and Hyperlipidemia
COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?
Liraglutide Shows CV Benefit: Clinical Perspectives on the LEADER Trial
Hypoglycemia Is BAD.
Improving Effective Basal Insulin Use in Clinical Practice
Are All Novel Insulins Proven to Be Equally Safe?
Emerging Combination Injectable Therapy A New Era in Diabetes Care
INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.
Anemia Explored.
Fixed-Ratio Combination Therapy in T2DM
Risk Stratification in MDS
An insulin simplification regimen: from multiple injections to once-daily long-acting (basal) insulin plus noninsulin agents. *Basal insulins: glargine.
Emerging Basal Insulins for Diabetes
Fresh perspectives ON BASAL Insulins in diabetes care
The Challenge of Insulin Titration
Presentation transcript:

Modern Strategies for Insulin Use in Today's Type 2 Diabetes Treatment Era

Short-, Intermediate-, Long-Acting Insulins

Clinical Practice Assessment Question

Role of Insulin U-500 in Patients With Extreme Insulin Resistance

Insulin Glargine U-300 Less Nocturnal Hypoglycemia vs U-100

Insulin Degludec* An Ultra-Long-Acting Basal Insulin Analog

Clinical Practice Assessment Question

On the Horizon: Biosimilar Insulins First Biosimilar Insulin Glargine

Insulin Peglispro/BIL* A Novel, Polyethylene Glycolylated Insulin

Clinical Practice Assessment Question

Abbreviations

References

References (cont)

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.